Melatonin May Increase Anticancer Potential of Pleiotropic Drugs

Melatonin (N-acetyl-5-methoxytryptamine) is not only a pineal hormone, but also an ubiquitary molecule present in plants and part of our diet. Numerous preclinical and some clinical reports pointed to its multiple beneficial effects including oncostatic properties, and as such, it has become one of...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2018-12, Vol.19 (12), p.3910
Main Authors: Bojková, Bianka, Kubatka, Peter, Qaradakhi, Tawar, Zulli, Anthony, Kajo, Karol
Format: Article
Language:English
Subjects:
Animals
Anti-inflammatory agents
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antidiabetics
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bioavailability
Cancer
Cancer therapies
Cell cycle
Clinical Trials as Topic
Drug Synergism
Drugs
Endocrine system
Food
Fruits
Herbal medicine
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Inflammation
Melatonin
Melatonin - pharmacology
Melatonin - therapeutic use
Metabolic disorders
Metabolism
Neoplasms - drug therapy
Neoplasms - metabolism
Nonsteroidal anti-inflammatory drugs
NSAIDs
Nuts
Pineal gland
Review
Signal Transduction - drug effects
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melatonin (N-acetyl-5-methoxytryptamine) is not only a pineal hormone, but also an ubiquitary molecule present in plants and part of our diet. Numerous preclinical and some clinical reports pointed to its multiple beneficial effects including oncostatic properties, and as such, it has become one of the most aspiring goals in cancer prevention/therapy. A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too. Adjuvant therapy with melatonin may improve the oncostatic potential of these drugs. Results from preclinical studies are limited though support this hypothesis, which, however, remains to be verified by further research.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms19123910